Axsome Therapeutics
AXSM
171 hedge funds and large institutions have $627M invested in Axsome Therapeutics in 2021 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 67 increasing their positions, 39 reducing their positions, and 37 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 39
5% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 37
3% less funds holding
Funds holding: 176 → 171 (-5)
8.94% less ownership
Funds ownership: 59.54% → 50.59% (-8.9%)
15% less call options, than puts
Call options by funds: $49M | Put options by funds: $57.3M
58% less capital invested
Capital invested by funds: $1.51B → $627M (-$880M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$15.6M |
| 2 |
New York State Teachers Retirement System (NYSTRS)
Albany,
New York
|
+$12.6M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$10.8M |
| 4 |
Jane Street
New York
|
+$7.43M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$112M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$34.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.4M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$27.5M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$24.3M |
AXSM Hedge Fund Activity: Q3 2021 in Review
171 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2021, worth a combined $627M — down 58% from $1.51B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of AXSM and 35 opened new positions — a net loss of 2 holders — while 39 trimmed existing stakes and 67 added.
The largest buyer was Bellevue Group, adding an estimated $15.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $112M sold.
- 171 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2021, down from 176 in Q2 2021.
- Funds reported $627M of Axsome Therapeutics stock for Q3 2021, down 58% quarter-over-quarter.
- 35 funds opened new Axsome Therapeutics positions in Q3 2021 and 37 closed out, a net change of -2 holders.
- The largest Axsome Therapeutics buyer in Q3 2021 was Bellevue Group, an estimated $15.6M added.
- The largest Axsome Therapeutics seller in Q3 2021 was RA Capital Management, an estimated $112M sold.
Based on aggregated 13F filings for Q3 2021.